TISSUE THERAPIES LIMITED (TIS)



Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!


General Information
Company Name: Tissue Therapies Limited
Stock Code: TIS
Website: www.tissuetherapies.com
GICS Sub-Industry: Biotechnology
Market Cap ($M): 27
Equiv. Shares (M): 214

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.125 $ 0.125 $ 0.125 $ 0.120 $ 0.120 140,848 $ 0.005  4.167 %

Current Broker Consensus Recommendation more
Recommendation: Hold
Recommendation Date: 19th Mar 2013
12 Month Target Price (average): $0.14
Brokers Surveyed: 1

Company Overview

Business Description:
Tissue Therapies Limited (TIS) is an Australian biomedical technology company which develops treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. TIS is commercialising VitroGro ECM, a technology for cell based therapies. TIS is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate.


Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  F 6.7 3.9 -- 3.2 -- 0.0 --
2013  F -1.5 -0.9 -- -- -- 0.0 --
2012  A -6.8 -4.0 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
CSL (CSL) $30,043 M 0.0878 0.2981 0.1367 32.2213 24.8215 21.8366 0.0136 0.0173 0.0195
Mesoblast (MSB) $1,735 M -- -- -- -- -- -- 0.0000 0.0000 0.0000
Starpharma (SPL) $252 M -- -- -- -- -- -- 0.0000 0.0000 0.0000
Sirtex Medical (SRX) $601 M 0.4803 0.9070 0.3577 35.6954 18.7185 13.7869 0.0093 0.0178 0.0237
Tissue Therapies (TIS) $26 M -- -- -- -- -- 3.0534 0.0000 0.0000 0.0000

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
TIS -- -- 2.02 -- 62.5
Market 1.10 12.9 0.91 2.56 2.61
Sector 0.93 20.8 2.40 0.55 7.03

Directors
Name Position Start Date
Mr Roger Brian Clarke Chairman 06 November 2003
Dr Steven John Mercer Chief Executive Officer,Managing Director 10 May 2006
Dr Cherrell Hirst Non-Executive Director 30 June 2009
Mr Iain Gladstone Ross Non-Executive Director 25 May 2012
Mr Melvyn John Bridges Non-Executive Director 12 March 2009

Management
Name Position
Drummond McKenzie Chief Finance Officer,Company Secretary
Zee Upton Chief Scientific Officer
Saskia Jo Corporate Accountant
Gary Shooter Director of Research and Development
Brian Ziegelaar International Product Manager
Andrew Thelwell Managing Director, EU Commercial Operations
Eva-Lisa Heinrichs Medical Director, Global Medical Affairs
Nigel Johnson Operations Director
Hedie Meka Regulatory and Intellectual Property Manager

Substantial Shareholders
Holding Name
22,985,000 (13.33%) Asia Union Investments Pty Ltd

Calendar of Events
Date Event
19 February 2014 Report (Interim)
04 October 2013 Report (Annual)
20 August 2013 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.

Advertisement

Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Fixed Income

An educational booklet with information on how to earn more than bank interest on the cash in your investment portfolio.

More details...

News

Killing a golden goose

The Age 22/05/2013 | A piece of broker research came out last week that described the budget as a sensible one but an almost suicidal one for a government four months out from an election. Instead of trying to buy votes, it seemed intent instead on putting as many noses out of joint as it possibly could.

Tinkering undermines the system

The Age 22/05/2013 | In last week's budget, the government missed what will probably be its last opportunity to make the superannuation system fairer and more sustainable. While the government made some tough decisions, such as reneging on promised tax cuts, one of the fastest-growing expenses is the tax concessions for superannuation.

Exposure appeals as recession looms

The Age 22/05/2013 | What chance recession?

The cuts are now personal Grinding out the numbers

The Age 22/05/2013 | Baby, forget the bonus. With tax concessions gone the federal government's budget could also affect your health, writes John Collett.

The mother of all super shortfalls

The Age 22/05/2013 | Last week's budget was a bit of aho-hum affair on many levels related to superannuation, because most of the changes to the system had been announced back in April. The transfer of the Baby Bonus into an extra (reduced) payment for families eligible for Family Tax Benefit Part A, has drawn the light fairly and squarely on the costs of bearing and raising children. The recent debate about the opposition's Paid Parental Scheme versus the government's less-generous scheme has added fuel to the fire.

Tradies call for rescue after builder collapse

The Age 22/05/2013 | Tradies caught out by the collapse of National Buildplan Group have called for a financial "rescue" package and an investigation into the failure of the company.

More...


Sponsored Links

Feedback Form